| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $30,711,668 | 5 | 71 |
Sells | $4,971 | 2 | 29 |
| RA CAPITAL MANAGEMENT, L.P. | 1 | $30M | 0 | $0 | $30M | |
| Oxford Science Enterprises plc | Former 10% Owner | 1 | $640,000 | 0 | $0 | $640,000 |
| McArthur James G | President and CEO | 2 | $61,275 | 0 | $0 | $61,275 |
| STRECK PAUL | EVP, Head of R&D | 1 | $10,393 | 0 | $0 | $10,393 |
| DeLena Mary Beth | General Counsel | 0 | $0 | 1 | $2,406 | $-2,406 |
| Donnelly Noel | Chief Financial Officer | 0 | $0 | 1 | $2,565 | $-2,565 |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at PepGen Inc. have bought $30.71M and sold $4,971 worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $18.51M and sold $553,564 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $30M. Oxford Science Enterprises plc (Former 10% Owner) — $640,000. McArthur James G (President and CEO) — $61,275.
The last purchase of 200,000 shares for transaction amount of $640,000 was made by Oxford Science Enterprises plc (Former 10% Owner) on 2025‑09‑30.
| 2025-09-30 | Oxford Science Enterprises plc | Former 10% Owner | 200,000 0.4223% | $3.20 | $640,000 | +14.61% | ||
| 2025-09-26 | RA CAPITAL MANAGEMENT, L.P. | 9.38M 18.0403% | $3.20 | $30M | +3.90% | |||
| 2025-05-30 | STRECK PAUL | EVP, Head of R&D | 8,375 0.0218% | $1.24 | $10,393 | +82.19% | ||
| 2025-04-17 | McArthur James G | President and CEO | 10,000 0.0377% | $1.35 | $13,550 | +18.80% | ||
| 2025-04-08 | McArthur James G | President and CEO | 41,500 0.1327% | $1.15 | $47,725 | +54.00% | ||
| 2025-02-26 | Sale | Donnelly Noel | Chief Financial Officer | 1,527 0.005% | $1.68 | $2,565 | +3.59% | |
| 2025-02-26 | Sale | DeLena Mary Beth | General Counsel | 1,432 0.0047% | $1.68 | $2,406 | +3.59% | |
| 2024-07-25 | Sale | Mellion Michelle L | Chief Medical Officer | 7,571 0.0234% | $18.06 | $136,741 | -86.54% | |
| 2024-07-24 | Sale | Mellion Michelle L | Chief Medical Officer | 201 0.0006% | $18.01 | $3,619 | -86.05% | |
| 2024-07-18 | Sale | Mellion Michelle L | Chief Medical Officer | 12,625 0.0427% | $18.20 | $229,804 | -83.87% | |
| 2024-07-16 | Sale | Mellion Michelle L | Chief Medical Officer | 5,901 0.0194% | $18.00 | $106,247 | -84.42% | |
| 2024-07-12 | Sale | Mellion Michelle L | Chief Medical Officer | 3,288 0.0108% | $18.04 | $59,331 | -81.29% | |
| 2024-07-02 | Sale | Mellion Michelle L | Chief Medical Officer | 37 0.0001% | $18.07 | $669 | -76.65% | |
| 2024-07-01 | Sale | Mellion Michelle L | Chief Medical Officer | 875 0.0029% | $18.01 | $15,760 | -78.62% | |
| 2024-06-24 | Sale | Mellion Michelle L | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -77.16% | |
| 2024-06-12 | Sale | Mellion Michelle L | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -75.13% | |
| 2024-06-11 | Sale | Mellion Michelle L | Chief Medical Officer | 500 0.0016% | $18.04 | $9,022 | -75.22% | |
| 2024-06-06 | Sale | Mellion Michelle L | SVP, Clinical Development | 1,411 0.0045% | $18.00 | $25,398 | -74.05% | |
| 2024-06-05 | Sale | Mellion Michelle L | SVP, Clinical Development | 7,245 0.0223% | $18.09 | $131,062 | -75.06% | |
| 2024-05-17 | Sale | Svenstrup Niels | SVP, Chem. Mfg & Controls | 10,000 0.0306% | $13.41 | $134,100 | -57.22% |
| RA CAPITAL MANAGEMENT, L.P. | 18554273 26.9887% | $96.48M | 2 | 0 | <0.0001% | |
| Oxford Science Enterprises plc | Former 10% Owner | 4955388 7.208% | $25.77M | 2 | 0 | +7.35% |
| McArthur James G | President and CEO | 113913 0.1657% | $592,347.60 | 3 | 5 | +115.1% |
| STRECK PAUL | EVP, Head of R&D | 27805 0.0404% | $144,586.00 | 1 | 0 | |
| Donnelly Noel | Chief Financial Officer | 1673 0.0024% | $8,699.60 | 0 | 1 | |
| DeLena Mary Beth | General Counsel | 1568 0.0023% | $8,153.60 | 0 | 1 | |
| Shah Rajeev M. | 1302600 1.8947% | $6.77M | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 0.6936% | $2.48M | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.0061% | $21,663.20 | 1 | 0 | <0.0001% |
| Svenstrup Niels | SVP, Chem. Mfg & Controls | 0 0% | $0 | 0 | 1 | |
| Goyal Jaya | EVP, Res. & Preclin. Dev. | 0 0% | $0 | 0 | 4 | |
| Mellion Michelle L | Chief Medical Officer | 0 0% | $0 | 0 | 12 |
$5,960,789 | 91 | -7.17% | $344.7M | |
$69,137,799 | 70 | 25.27% | $326.54M | |
$5,911,307 | 70 | -1.38% | $404.4M | |
$54,836,085 | 68 | -0.52% | $391.56M | |
$17,468,215 | 46 | 18.85% | $394.49M | |
$24,384,691 | 42 | -30.27% | $374.21M | |
$63,049,419 | 31 | 2.87% | $337.52M | |
$54,828,550 | 26 | -13.88% | $360.9M | |
$4,306,464 | 21 | 37.34% | $406.02M | |
$22,365,077 | 19 | -27.47% | $351.35M | |
$104,137,421 | 15 | 21.28% | $393.93M | |
$65,355,913 | 13 | -3.42% | $318.79M | |
$57,263,116 | 11 | -8.37% | $366.31M | |
$17,675,244 | 7 | 92.20% | $320.99M | |
PepGen Inc. (PEPG) | $43,326,461 | 6 | 16.01% | $357.49M |
$88,549,962 | 5 | -16.91% | $352.6M | |
$4,745,999 | 5 | -4.91% | $312.76M | |
$4,888,000 | 3 | -20.50% | $352.66M | |
$20,020,000 | 1 | -75.24% | $366.1M |
| Increased Positions | 51 | +80.95% | 36M | +157.11% |
| Decreased Positions | 30 | -47.62% | 3M | -12.91% |
| New Positions | 32 | New | 21M | New |
| Sold Out Positions | 12 | Sold Out | 818,025 | Sold Out |
| Total Postitions | 84 | +33.33% | 57M | +144.2% |
| Ra Capital Management, L.P. | $143,863.00 | 29.08% | 20.06M | +9M | +87.7% | 2025-09-30 |
| Viking Global Investors Lp | $24,969.00 | 5.05% | 3.48M | +2M | +134.91% | 2025-09-30 |
| Commodore Capital Lp | $16,902.00 | 3.42% | 2.36M | +2M | New | 2025-09-30 |
| Vivo Capital, Llc | $16,670.00 | 3.37% | 2.33M | +2M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $14,555.00 | 2.94% | 2.03M | -729,171 | -26.43% | 2025-09-30 |
| Bvf Inc/Il | $13,731.00 | 2.78% | 1.92M | +2M | New | 2025-09-30 |
| Laurion Capital Management Lp | $13,567.00 | 2.74% | 1.89M | +1M | +133.38% | 2025-09-30 |
| Vanguard Group Inc | $12,679.00 | 2.56% | 1.77M | +831,333 | +88.72% | 2025-09-30 |
| Rtw Investments, Lp | $10,755.00 | 2.17% | 1.5M | +2M | New | 2025-09-30 |
| Janus Henderson Group Plc | $10,755.00 | 2.17% | 1.5M | +2M | New | 2025-09-30 |